Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$12.78 USD
-0.22 (-1.69%)
Updated May 20, 2024 04:00 PM ET
After-Market: $12.76 -0.02 (-0.16%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRNA 12.78 -0.22(-1.69%)
Will VRNA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRNA
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade
Other News for VRNA
Strategic Financing Secures Verona Pharma’s Future Beyond 2026, Ensuring Buy Rating
Positive Outlook for Verona Pharma with Strong Financial Position and Anticipated Drug Approval
Verona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic Overview
Truist Financial Keeps Their Buy Rating on Verona Pharma (VRNA)
Verona Pharma gets $650M in financing ahead of June FDA decision on COPD asset